Kidney disease: We are using three-dimensional organoids and other tissue models to identify drugs that reverse autosomal dominant polycystic kidney disease. This genetic disorder often progresses to end-stage renal disease, which currently can only be treated with dialysis or transplantation. Liver disease: Our researchers are evaluating therapeutic opportunities for patients with acute liver failure and non-alcoholic steatohepatitis (NASH), and want to promote liver regeneration for other acute and chronic liver conditions. Fibrosis: We are also building a cross-organ research group to tackle the underlying mechanisms of fibrotic diseases. This new endeavor will focus on targets and pathways that are applicable across several systems with the expectation of developing therapeutics that address multiple fibrotic indications.